Selected Quarterly Financial Data (unaudited) (Tables)

12 Months Ended

Sep. 30, 2019

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Information

Quarterly financial information for fiscal 2019 and 2018 is presented in the following table:

	2019 Quarter Ended
	December 31, 2018			March 31, 2019		June 30, 2019		September 30, 2019
	(in thousands, except per share data)
Revenue	$	69,886		$	39,631	$	44,367	$	51,313
Operating expenses		42,030			40,935		40,612		44,882
Other income (expense), net		1,885			2,245		2,415		2,274
Income tax benefit (expense)		(3,730	)		3,204		866		486
Net income		26,011			4,145		7,036		9,191
Net income per common share — basic(2)	$	1.34		$	0.21	$	0.36	$	0.47
Net income per common share — diluted(2)	$	1.25		$	0.20	$	0.33	$	0.44

	2018 Quarter Ended
	December 31, 2017			March 31, 2018			June 30, 2018			September 30, 2018
	(in thousands, except per share data)
Revenue (1)	$	38,109		$	44,049		$	57,262		$	67,205
Operating expenses		23,732			27,190			34,622			32,753
Other income (expense), net		960			1,066			1,338			1,429
Income tax (expense)		(3,644	)		(5,370	)		(3,690	)		(8,461	)
Net income		11,693			12,555			20,288			27,420
Net income per common share — basic(2)	$	0.61		$	0.65		$	1.05		$	1.41
Net income per common share — diluted(2)	$	0.59		$	0.61		$	0.97		$	1.30

(1) During the first quarter of 2018, the Company recognized $15,000 in milestone revenue from AbbVie upon achievement of commercialization regulatory approval of AbbVie’s glecaprevir-containing regimen in Japan.

(2) The earnings per share amounts for each quarter may not sum to the fiscal year amounts due to rounding and the effect of weighting.